Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2022 16:05 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

- SNS-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-PD-1 antibodies and a significantly improved cytokine release profile as compared to a...
September 21, 2022 16:05 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for...
June 01, 2022 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer,...
May 25, 2022 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference

BOSTON, May 25, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
May 10, 2022 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - - Cash runway extended into the first quarter of...